United Laboratories Unit's Chronic Kidney Disease Drug Gets US Clinical Trial Approval

MT Newswires Live

2025/03/04

United Laboratories International Holdings (HKG:3933) said its subsidiary's UBT251 drug received approval from the US Food and Drug Administration for a Phase II clinical trial targeting chronic kidney disease (CKD), according to a Monday filing with the Hong Kong Exchange.

Based on the preclinical obesity/diabetic nephropathy pharmacodynamic model, UBT251

demonstrated "significantly superior overall improvement effects on renal urinary albumin and

other related renal injury markers and histopathology than Semaglutide," United Laboratories said.

UBT251, developed by United Laboratories subsidiary The United Bio-Technology (Hengqin), received clinical trial authorization in China in January for the same indication.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2516191610"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516191610\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2516191610?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-04 14:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516191610","market":"fut","top_or_hot":-1,"title":"United Laboratories Unit's Chronic Kidney Disease Drug Gets US Clinical Trial Approval","media":"MT Newswires Live","content":"<html><body><p> United Laboratories International Holdings (HKG:3933) said its subsidiary's UBT251 drug received approval from the US Food and Drug Administration for a Phase II clinical trial targeting chronic kidney disease (CKD), according to a Monday filing with the Hong Kong Exchange.</p><p>Based on the preclinical obesity/diabetic nephropathy pharmacodynamic model, UBT251</p><p>demonstrated \"significantly superior overall improvement effects on renal urinary albumin and</p><p>other related renal injury markers and histopathology than Semaglutide,\" United Laboratories said.</p><p>UBT251, developed by United Laboratories subsidiary The United Bio-Technology (Hengqin), received clinical trial authorization in China in January for the same indication.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Laboratories Unit's Chronic Kidney Disease Drug Gets US Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Laboratories Unit's Chronic Kidney Disease Drug Gets US Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-04 14:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> United Laboratories International Holdings (HKG:3933) said its subsidiary's UBT251 drug received approval from the US Food and Drug Administration for a Phase II clinical trial targeting chronic kidney disease (CKD), according to a Monday filing with the Hong Kong Exchange.</p><p>Based on the preclinical obesity/diabetic nephropathy pharmacodynamic model, UBT251</p><p>demonstrated \"significantly superior overall improvement effects on renal urinary albumin and</p><p>other related renal injury markers and histopathology than Semaglutide,\" United Laboratories said.</p><p>UBT251, developed by United Laboratories subsidiary The United Bio-Technology (Hengqin), received clinical trial authorization in China in January for the same indication.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UBCP","symbol_name":"联合合众银行","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2516191610","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516191610","pubTimestamp":1741070639,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"United Laboratories International Holdings  said its subsidiary's UBT251 drug received approval from the US Food and Drug Administration for a Phase II clinical trial targeting chronic kidney disease , according to a Monday filing with the Hong Kong Exchange.Based on the preclinical obesity/diabetic nephropathy pharmacodynamic model, UBT251demonstrated \"significantly superior overall improvement effects on renal urinary albumin andother related renal injury markers and histopathology than Semaglutide,\" United Laboratories said.UBT251, developed by United Laboratories subsidiary The United Bio-Technology , received clinical trial authorization in China in January for the same indication.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UBCP":"联合合众银行","BK4211":"区域性银行","BK1191":"制药","03933":"联邦制药"},"translate_title":"联邦制药子公司慢性肾病药物获得美国临床试验批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UBCP":1,"03933":0.9},"content_text":"United Laboratories International Holdings (HKG:3933) said its subsidiary's UBT251 drug received approval from the US Food and Drug Administration for a Phase II clinical trial targeting chronic kidney disease (CKD), according to a Monday filing with the Hong Kong Exchange.Based on the preclinical obesity/diabetic nephropathy pharmacodynamic model, UBT251demonstrated \"significantly superior overall improvement effects on renal urinary albumin andother related renal injury markers and histopathology than Semaglutide,\" United Laboratories said.UBT251, developed by United Laboratories subsidiary The United Bio-Technology (Hengqin), received clinical trial authorization in China in January for the same indication.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}